Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections.
Patients with human immunodeficiency virus infection and the acquired immunodeficiency syndrome are often treated with a variety of potentially nephrotoxic drugs. This review summarizes the renal, fluid, and electrolyte complications of drugs used to treat human immunodeficiency virus and associated opportunistic infections. The pharmacokinetics of the drugs are also briefly reviewed, and dosing guidelines for the use of these drugs in patients who have renal insufficiency or who are receiving dialysis are provided.
Berns
J S
JS
Division of Nephrology and Hypertension, Graduate Hospital, Philadelphia, PA 19146.
Cohen
R M
RM
Stumacher
R J
RJ
Rudnick
M R
MR
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D000935:Antifungal Agents / Q000009:adverse effects; D000981:Antiprotozoal Agents / Q000009:adverse effects; D000998:Antiviral Agents / Q000009:adverse effects; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000139:chemically induced / Q000150:complications; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000935:Antifungal Agents; D000981:Antiprotozoal Agents; D000998:Antiviral Agents